---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-010901"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:02:53.098123+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma regains NYSE American continued listing compliance

## Summary
- Received notification on March 21, 2024, resolving low selling price deficiency under Section 1003(f)(v).
- Common stock demonstrated sustained price improvement, curing the non-compliance.
- '.BC' indicator discontinued at market open on March 22, 2024; removed from noncompliant issuers list.
- NYSE American confirmed continued listing standard is now satisfied.

## SEC filing metadata
- accession: 0001493152-24-010901
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315224010901/0001493152-24-010901-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315224010901/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-010901
- JSON: https://secwatch.observer/filing/0001493152-24-010901.json
- Plain text: https://secwatch.observer/filing/0001493152-24-010901.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.